Literature DB >> 35376966

[Atypical femoral fracture : Pitfalls in surgical treatment].

J C Hopf1, P M Rommens2, P Drees2, F Traub2, D Wagner2.   

Abstract

Atypical femoral fractures are a very rare complication after treatment with bisphosphonates. This case report describes the diagnostic criteria and some particularities of the surgical treatment. Atypical femoral fractures are typically stabilized with intramedullary nails but some pitfalls in surgical treatment, e.g. the choice of implant, have to be considered. Basically, these fractures can be treated using conventional intramedullary nails, which, however, must be used by being adapted depending on the morphology of the femur. The fact that atypical femoral fractures can occur under bisphosphonate treatment should in no way influence the indications for starting anti-osteoporotic treatment.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Bisphosphonates; Femur; Nailing; Osteoporosis; Osteosynthesis

Year:  2022        PMID: 35376966     DOI: 10.1007/s00113-022-01171-2

Source DB:  PubMed          Journal:  Unfallchirurg        ISSN: 0177-5537            Impact factor:   1.000


  9 in total

Review 1.  Surgical Treatment of the Atypical Femoral Fracture: Overcoming Femoral Bowing.

Authors:  Kyung-Jae Lee; Byung-Woo Min
Journal:  Hip Pelvis       Date:  2018-12-06

Review 2.  Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management.

Authors:  A Koh; E Guerado; P V Giannoudis
Journal:  Bone Joint J       Date:  2017-03       Impact factor: 5.082

3.  Scoring System for Identifying Impending Complete Fractures in Incomplete Atypical Femoral Fractures.

Authors:  Byung-Woo Min; Kyung-Hoi Koo; Youn-Soo Park; Chang-Wug Oh; Seung-Jae Lim; Joon-Woo Kim; Kyung-Jae Lee; Young-Kyun Lee
Journal:  J Clin Endocrinol Metab       Date:  2017-02-01       Impact factor: 5.958

4.  Progression of Asymptomatic Contralateral Femur in Patients with Complete Atypical Femoral Fracture, According to Initial Radiographic Findings.

Authors:  Kyung-Jae Lee; Byung-Woo Min; Ki-Cheor Bae; Chul-Hyun Cho; Si-Wook Lee; Beom-Soo Kim
Journal:  J Bone Joint Surg Am       Date:  2021-01-20       Impact factor: 5.284

Review 5.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

6.  Healing Time and Complications in Operatively Treated Atypical Femur Fractures Associated With Bisphosphonate Use: A Multicenter Retrospective Cohort.

Authors:  Yelena Bogdan; Paul Tornetta; Thomas A Einhorn; Pierre Guy; Lise Leveille; Juan Robinson; Michael J Bosse; Nikkole Haines; Daniel Horwitz; Clifford Jones; Emil Schemitsch; Claude Sagi; Bryan Thomas; Daniel Stahl; William Ricci; Megan Brady; David Sanders; Michael Kain; Thomas F Higgins; Cory Collinge; Stephen Kottmeier; Darin Friess
Journal:  J Orthop Trauma       Date:  2016-04       Impact factor: 2.512

7.  Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.

Authors:  Dennis M Black; Erik J Geiger; Richard Eastell; Eric Vittinghoff; Bonnie H Li; Denison S Ryan; Richard M Dell; Annette L Adams
Journal:  N Engl J Med       Date:  2020-08-20       Impact factor: 91.245

8.  The enigma of atypical femoral fractures: A summary of current knowledge.

Authors:  Morten Schultz Larsen; Hagen Schmal
Journal:  EFORT Open Rev       Date:  2018-09-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.